

Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-InsulinProducing Cells Expression"

Bibhu Prasad Panda

Potential competing interests: No potential competing interests to declare.

As per retrospective analysis and scientific evidence cited in the manuscript entitled 'Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression Insulin Degludec' has significant potential for further study and translation to clinical study. The proposed clinical trial and investigation on the synergistic impact of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes treatment can provide valuable insights for futuristic treatment and management of Type 1 Diabetes. Semaglutide GLP1 Agonists, Degludec Basal-bolus Insulin, prandial insulin and their dosage regimen have a greater impact on the management of newly diagnosed Type 1 Diabetes, as evident in retrospective analysis of the efficacy of semaglutide in patients with newly diagnosed type 1 diabetes. A scientifically optimized dosage regimen could be considered in clinical trial protocol design, which contributes a significant impact on the overall therapeutic outcomes of the proposed study. The investigations on how GLP-1 agonists alone and in combination with Degludec have an impact in protecting residual beta cells, stimulating cell proliferation, reprogramming liver cells into insulin-producing cells, preventing antibodies against glutamic acid decarboxylase, monitoring autoimmune response in the proposed clinical trial could provide valuable insight to validate the hypothesis of the study.